Intolerance to 5-aminosalicylate is a risk of poor prognosis in ulcerative colitis patients

被引：0
|
作者：
Fujii, T. [1 ]
Hibiya, S. [1 ]
Maeyashiki, C. [2 ]
Saito, E. [1 ]
Takenaka, K. [1 ]
Motobayashi, M. [1 ]
Shimizu, H. [1 ]
Nagahori, M. [1 ]
Ohtsuka, K. [1 ]
Kurosaki, M. [2 ]
Yauchi, T. [3 ]
Watanabe, M. [1 ]
机构：
[1] Tokyo Med & Dent Univ, Dept Gastroenterol & Hepatol, Tokyo, Japan
[2] Musashino Red Cross Hosp, Gastroenterol, Tokyo, Japan
[3] Soka Municipal Hosp, Gastroenterol, Soka, Japan
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P461
引用
收藏
页码：S409 / S410
页数：2
相关论文
共 50 条
  • [11] THERAPEUTIC EFFECT OF METHYL 5-AMINOSALICYLATE ON EXPERIMENTAL ULCERATIVE-COLITIS IN RABBITS
    LIAO, YZ
    CHEN, ZH
    CHEN, SY
    HUANG, YF
    ZHU, KQ
    ZHUO, GZ
    ACTA PHARMACOLOGICA SINICA, 1990, 11 (01): : 54 - &
  • [12] Simulated Comparison of Topical and Oral Formulations of 5-Aminosalicylate for the Treatment of Ulcerative Colitis
    Stobaugh, Derrick J.
    Deepak, Parakkal
    Thorpe, Matthew
    Hannon, Bruce
    Ehrenpreis, Eli D.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (02) : 301 - 308
  • [13] Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis
    Sandborn, MJ
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (12): : 2939 - 2941
  • [14] Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial
    Balram, Bhairavi
    Joshi, Harshad
    Wong, Karen
    Kroeker, Karen I.
    Dieleman, Levinus A.
    Halloran, Brendan P.
    Baumgart, Daniel C.
    Peerani, Farhad
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (11) : 3985 - 3992
  • [15] Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial
    Bhairavi Balram
    Harshad Joshi
    Karen Wong
    Karen I. Kroeker
    Levinus A. Dieleman
    Brendan P. Halloran
    Daniel C. Baumgart
    Farhad Peerani
    Digestive Diseases and Sciences, 2021, 66 : 3985 - 3992
  • [16] Peripheral T-cell lymphoma mimicking 5-aminosalicylate hypersensitivity in ulcerative colitis
    Kong, L. M.
    Fok, K. C.
    Tsui, A.
    Qian, C.
    Fisher, L.
    INTERNAL MEDICINE JOURNAL, 2013, 43 (10) : 1137 - 1140
  • [17] Co-prescribing Azathiopurine or 6-Mercaptopurine and 5-Aminosalicylate Compounds in Ulcerative Colitis
    Mayberry, H.
    Moshkovska, T.
    Mayberry, J. F.
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (02) : 190 - 192
  • [18] Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis
    Shaffer, Seth R.
    Huang, Elbert
    Patel, Shivani
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (01): : 125 - 133
  • [19] 5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis
    Hibiya, Shuji
    Matsuyama, Yusuke
    Fujii, Toshimitsu
    Maeyashiki, Chiaki
    Saito, Eiko
    Ito, Kimiko
    Shimizu, Hiromichi
    Kawamoto, Ami
    Motobayashi, Maiko
    Takenaka, Kento
    Nagahori, Masakazu
    Kurosaki, Masayuki
    Yauchi, Tsunehito
    Ohtsuka, Kazuo
    Fujiwara, Takeo
    Okamoto, Ryuichi
    Watanabe, Mamoru
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (01) : 103 - 113
  • [20] Renal failure in a 23-year-old man with ulcerative colitis treated with 5-aminosalicylate
    Villafuerte Ledesma, H. M.
    Pena Porta, J. M.
    Marta Casanova, C. B.
    Alvarez Lipe, R.
    REVISTA CLINICA ESPANOLA, 2019, 219 (08): : 451 - 457
12345